Emulsifier and antioxidant properties of by-products obtained by enzymatic degumming of soybean oil

The enzymes used in degumming, called phospholipases, specifically act on phospholipids without degrading the oil itself. Degumming using a phospholipase C enzyme allows to meet all market specifications while it increases the oil yield. The aim of this study was to evaluate antioxidant and emulsifier properties of the recovered gum (RG) obtained by enzymatic oil degumming process of crude soybean oil subjected to modifications as deoiling (RG deoiled) or ethanol fractionation (RG soluble and insoluble). RG soluble allowed obtaining more stable O/W emulsions (30:70 w/w) in comparison with those by-products assayed at different concentrations (0.1?1.0%). Also, deoiled soybean lecithin (DSL) andRG deoiled had a similar behavior in relation to the kinetic destabilization (%BS profiles), despite the different degumming processes used to obtain these samples. The study on induction times (Metrohm Rancimat) showed a significant antioxidant effect (p<0.05) against a refined sunflower oil associated with all the by-products analyzed. However, RG soluble and DSL showed a strong effect on the oil stability at high concentrations (1000?2000 ppm). These results showed that the deoiled recovered gum and its derivates obtained by ethanol fractionation are a potential alternative for industrial application as additive.Fil: Cabezas, Dario Marcelino. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas. Centro de Investigación y Desarrollo en Criotecnología de Alimentos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Criotecnología de Alimentos. Universidad Nacional de la Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Criotecnología de Alimentos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Diehl, B. W. K.. Spectral Service GmbH Laboratorium fur Auftragsanalytik. Cologne; AlemaniaFil: Tomas, Mabel Cristina. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas. Centro de Investigación y Desarrollo en Criotecnología de Alimentos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Investigación y Desarrollo en Criotecnología de Alimentos. Universidad Nacional de la Plata. Facultad de Ciencias Exactas. Centro de Investigación y Desarrollo en Criotecnología de Alimentos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin

PlaComOv-study: randomized controlled trial in the Netherlands

BACKGROUND Treatment of advanced stage ovarian cancer (ASOC) consists of surgery and chemotherapy. During surgery, it is important to remove all visible tumor (complete cytoreductive surgery (CRS)) because this improves survival compared to an optimal CRS (residual tumor: 0.1-1 cm3). If there are metastases at vulnerable structures such as the small intestine, it is difficult to achieve a complete CRS with conventional devices. GOAL During a multicenter randomized controlled trial, to investigate whether the use of the PlasmaJet during CRS is safe and effective to achieve a higher percentage of complete CRS in the treatment of women with ASOC. PROJECT DESIGN RESEARCH QUESTION Does the use of the PlasmaJet result to a higher percentage complete CRS in patients with ASOC? HYPOTHESIS Adding PlasmaJet to standard surgical equipment improves the rate of complete CRS by 15% STUDY DESIGN Single-blind, multicenter randomized controlled trial in the Netherlands STUDY POPULATION Inclusion criteria: ASOC FIGO stage IIIB-IV where radical surgery and chemotherapy is indicated and who are fit enough to undergo surgery (primary or interval CRS) Exclusion criteria: ovarian cancer FIGO stage I-IIIA, recurrent ovarian cancer, no epithelial ovarian cancer INTERVENTION Use of PlasmaJet during CRS USUAL CARE Use of standard surgical instruments during CRS RESULTS From February 2018-September 2020, 327 women with ASOC were included in the study. The intention-to-treat analysis demonstrates a percentage of complete CRS of 75.8% in the intervention group versus 67.6% in the control group (p=0.131). The per-protocol analysis, excluding women who did not undergo CRS, demonstrates a percentage complete CRS of 85.6% in the intervention group versus 71.5% in the control group (p=0.005). There was no significant differences in the secondary outcomes (complication rate, operative time, blood loss, hospitalization, colostomy). A difference in the percentage of colostomy is seen with 5.7% in the intervention group and 11.8% in the control group. The use of the PlasmaJet during CRS produces significantly less thermal damage than electrocoagulation treatment (0.15mm versus 0.33mm, p<0.001). The cost of treatment from diagnosis to the end of chemotherapy when using the PlasmaJet is significantly higher than when the PlasmaJet is not available with a difference of €1,249. Twelve months after surgery, women in the intervention group reported a higher QoL than women in the control group (p=0.005). As part of the implementation process, various training courses have been organized in a skills lab for surgeons and gynecologists. Intended results are the difference in disease-free and overall survival and a cost-effectiveness analysis. DISCUSSION We conclude that the use of the PlasmaJet improves the surgical outcome without an increase of the complication rate. We will wait for the long-term results (5 years after the last inclusion) to know whether the use of the PlasmaJet also results to a longer disease-free and overall survival. The main limitation of this study is that we did not randomize per-operatively, so all women with unresectable disease (shown during surgery) would be excluded from this study and we could really analyze the effect of the PlasmaJet. The data of the per-protocol analysis would be the final outcomes. An explanation for rejecting the hypothesis to show a 15% difference in complete CRS between the two groups is that surgery has become more extensive over time. This results in a higher percentage of complete CRS in the intervention group. Most results have been published in international journals. The results of QoL have been submitted

Controle da dor no pós-operatório

A dor é um fenômeno freqüente no pós-operatório e pode resultar em sofrimento e riscos desnecessários ao paciente. Estudos demonstram o inadequado alívio da dor após a cirurgia e sua relação com falhas na avaliação e falta de conhecimento sobre métodos analgésicos. O artigo discute o manejo da dor pós-operatória que inclui o uso de analgésicos antiinflamatórios não hormonais, opiáceos, intervenções cognitivo-comportamentais e alta tecnologia como cateter peridural e sistemas de analgesia controlada pelo paciente. Além disso, o adequado controle da dor inclui a discussão sobre aspectos éticos e econômicos